|ALL FISH Profile (Ph-Like)
Probes: PDGFRb (5q32), BCR/ABL1-ASS1 t(9;22), JAK2 (9p24.1), EPOR (19p13.2) and CRLF2 (Xp22.33/Yp11.32) are included in the ALL FISH (Ph-like) Profile. Probes may be ordered separately.
Disease(s): Philadelphia chromosome (Ph-like) acute lymphoblastic leukemia (ALL), B lymphoblastic leukemia/lymphoma.
See also the ALL FUSION PROFILE.
|ALL Fusion Profile
Detection of gene fusion transcripts in Acute Lymphoblastic Leukemia (ALL) from ribonucleic acid (RNA). RNA is isolated from bone marrow aspirates or peripheral blood and the cDNA sequence of targeted regions of the ABL1, ABL2, BCR, CRLF2, CSF1R, ETV6, IL2RB, IL3, JAK2, KMT2A, MEF2D, MLLT10, NUP98, PAX5, PDGFRB, PTK2B, RUNX1 ,TAL1, TCF3, TLX1, TLX3, TYK2, and ZNF384 genes is determined using next-generation sequencing (NGS) technology. This test will be performed at our Carlsbad location.
For comprehensive Ph-like ALL assessment consider ordering CRLF2 FISH & EPOR FISH concurrently. See also the ALL FISH PROFILE (Ph-Like)
|B-Cell Gene Rearrangement
Detection of clonal IgH gene rearragements by PCR of IgH framework regions 1, 2, 3 and joining regions. In addition, Ig Kappa gene rearrangement analysis is performed using specific oligonucleotides recognizing the Vk, intragenic and Jk regions. Testing is approved for specimens from the state of New York.
|CD2CD2, the E-rosette receptor, is an extremely broad T-cell marker. This antibody immunostains the vast majority of T-cells and a subset of natural killer (NK) - cell malignancies. Half of thymic B-cells are also CD2 positive.||Immunohistochemistry (IHC)|
|CD3The CD3 antigen is first detectable in early thymocytes and its appearance probably represents one of the earliest signs of commitment to the T-cell lineage. It has a cytoplasmic expression at early T-cell differentiation, then membranous expression. CD3 is the most specific T-cell antibody. CD3 is expressed in normal thymocytes, peripheral T-cells, NK cells, and Purkinje cells of cerebellum. In diseased cells, CD3 stains most T-cell lymphomas. Only rare B cell lymphomas may be positive for CD3.||Immunohistochemistry (IHC)|
|CD56CD56 recognizes two proteins of the neural cell adhesion molecule, the basic molecule expressed on most neuroectodermally-derived cell lines, tissues and neoplasms (e.g. retinoblastoma, medulloblastomas, astrocytomas, and neuroblastomas). It is also expressed on some mesodermally-derived tumors (rhabdomyosarcoma) and on natural killer cells. CD56 can be used as a marker for NK cell neoplasms. Some benign and malignant plasma cells are also positive. CD56 is often positive in neuroendocrine carcinomas.||Immunohistochemistry (IHC)|
|CD57CD57 is expressed on subpopulations of peripheral blood mononuclear cells, NK active cells and T-cells. Hematopoietic malignancies that are CD57+ include a minority of T-lymphoblastic leukemias, roughly three quarters of the indolent T-cell large granular lymphocytic leukemias, and a small portion of NK-cell lymphomas. It can be used to highlight small lymphoid cells in nodular lymphocytic predominant Hodgkin lymphoma.||Immunohistochemistry (IHC)|
|CD8CD8 is a T-cell marker for the detection of cytotoxic/suppressor T-cells. CD8 is also detected on NK cells, most thymocytes, a subpopulation of null cells, and bone marrow cells. This antibody is useful in evaluating T-cell lymphomas.||Immunohistochemistry (IHC)|
|Granzyme BGranzyme B antibody labels activated human cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. This marker can be a useful tool for the identification of anaplastic large cell lymphoma, large granular lymphocytic leukemias, hepatosplenic T-cell lymphomas, intestinal T-cell lymphomas, NK-like T-cell lymphomas, NK-cell lymphomas, nasal T/NK-cell lymphomas, and subcutaneous panniculitic T-cell lymphomas of T or NK phenotype.||Immunohistochemistry (IHC)|
Ki67 is a nuclear protein that is expressed in proliferating cells. Ki67 is preferentially expressed during late G1, S, M, and G2 phases of the cell cycle, while cells in the G0 (quiescent) phase are negative for this protein. Increased proliferative activity is associated with more aggressive tumor and decreased disease-free survival period.
|NeoARRAY™ SNP/Cytogenetic Profile
The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP microarray with over 2.6 million SNP and non-polymorphic markers for detection of copy number variants (deletions, duplications, and amplifications) and loss of heterozygosity or uniparental disomy (LOH or UPD) in any chromosome. Sensitivity and specificity for detection of copy number variants >400 kb is >99%. Testing may not reliably detect abnormalities present in less than 20% of the cells tested. Balanced rearrangements, including translocations and inversions, are not detectable by this method. Clients may request NeoARRAY on POC as the sole test, or they may order POC cytogenetics with reflex to NeoARRAY if the POC culture fails or if cytogenetic results are normal. For reflex orders, if there is no cell attachment or growth after 14 days in culture, a cytogenetics failure report will be issued and NeoARRAY will be performed. If there is limited cell attachment after 14 days in culture, NeoGenomics will contact the client for instructions. When array testing is not performed, a fee will be charged for DNA extraction (which is performed upon specimen receipt).
|PerforinPerforin is a protein found in cytoplasmic granules of cytotoxic T-lymphocytes (CTLs). CTLs bind to cells that express foreign antigens and induce them to lyse. Perforin expression is significantly induced in CD8 positive T-cells, but to lesser extent in gamma/delta T-cells and NK cells. This antibody may be of value in the detection of perforin in CTLs in severe cases of graft versus host disease, chronic renal rejection and peripheral T-cell lymphomas. In addition, perforin antibody may also be useful for the detection of NK cell lymphomas, all of which express the perforin protein.||Immunohistochemistry (IHC)|
|Standard Leukemia/Lymphoma Panel - 24 markers
Available as global and tech-only. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD13, CD14, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, kappa, and lambda.
|STAT3 Mutation Analysis
Bi-directional sequencing of STAT3 exons 13-21 encompassing the DNA binding and SH2 domains.
|T-Cell Receptor Beta Gene Rearrangement
This test provides qualitative detection of monoclonal T-cell receptor (TCR) beta gene rearrangements by PCR and fragment analysis according to BIOMED-2 consensus primer design. This test may be ordered concurrently with or after negative results in our T-Cell Receptor Gamma Gene Rearrangement assay for gamma gene rearrangements to improve TCR rearrangement detection by ~5% in T-cell leukemias/lymphomas.
|T-Cell Receptor Gamma Gene Rearrangement
Detection of clonal T-cell receptor gamma (TCRG) gene rearrangements by PCR of variable and joining regions. T-Cell Receptor Beta Gene Rearrangement is offered separately and may be added to this gamma gene test.
|T-Cell Receptor/LGL Add-On Flow Panel
Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD3, CD4, CD7, CD8, CD16, CD45, CD56, CD57, TCR alpha/beta, and TCR gamma/delta (10 markers).
|TIA1TIA1 (T-cell intracytoplasmic antigen) monoclonal antibody reacts with a 15 kDa cytoplasmic granule-associated protein, expressed in lymphocytes processing cytolytic potential. Most anaplastic large cell lymphomas react with TIA1. TIA1 also reacts with most large granular lymphocytic leukemias, hepatosplenic T-cell lymphomas, intestinal T-cell lymphomas, NK-like T-cell lymphomas, NK-cell lymphomas, nasal T/NK-cell lymphomas, subcutaneous T-cell lymphomas and pulmonary angiocentric lymphomas of T or NK phenotype. All B-cell lymphomas, Hodgkin and lymphoblastic leukemias are negative for TIA1.||Immunohistochemistry (IHC)|
|V-Beta T-Cell Clonality
Available as global test only. Markers are VB1, VB2, VB3, VB4, VB5.1, VB5.2, VB5.3, VB7.1, VB7.2, VB8, VB9, VB11, VB12, VB13.1, VB13.2, VB13.6, VB14, VB16, VB17, VB18, VB20, VB21.3, VB22, and VB23 (24 markers). Two additional T-cell markers are used to identify the population of interest and the markers vary from case to case.
|Wright GiemsaCytochemical stain. The Wright Giemsa stain is used to stain peripheral blood and bone marrow smears for study of blood cell morphology.||Immunohistochemistry (IHC)|
Displaying 1 - 20 of 20 tests